| pubmed-article:8189254 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C1511649 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C0206529 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C0596131 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C1415306 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8189254 | lifeskim:mentions | umls-concept:C0210574 | lld:lifeskim |
| pubmed-article:8189254 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8189254 | pubmed:dateCreated | 1994-6-21 | lld:pubmed |
| pubmed-article:8189254 | pubmed:abstractText | The in vivo anticonvulsant effects and in vitro metabotropic glutamate receptor selectivity of (S)-4-carboxy-3-hydroxy-phenylglycine [(S)-4C3HPG] were examined. Intracerebroventricular injection of (S)-4C3HPG dose-dependently antagonized audiogenic-induced clonic and tonic convulsions in DBA/2 mice with ED50 values of 76 and 110-nmol per mouse, respectively. (S)-4C3HPG dose-dependently inhibited the spontaneously evoked epileptic spikes in a cingulate cortex-corpus callosum slice preparation. (S)-4C3HPG displaced the binding of [3H]glutamate in membranes prepared from baby hamster kidney (BHK) cells expressing the metabotropic glutamate receptor mGluR1a with an EC50 of 5 +/- 1 microM. (S)-4C3HPG dose-dependently antagonized glutamate-stimulated phosphoinositide hydrolysis in BHK cells expressing mGluR1a with an IC50 of 15 +/- 3 microM. (S)-4C3HPG was, however, an agonist at mGluR2 with an EC50 of 21 +/- 4 microM for inhibition of forskolin-stimulated cyclic AMP formation in BHK cells expressing the mGluR2. (S)-4C3HPG had no effects at mGluR4a. These data suggest that the anticonvulsant action of (S)-4C3HPG is mediated by combined antagonism of mGluR1a and agonism of mGluR2. These results suggest the importance of mGluR1a and/or mGluR2 in the control of epileptic activity. | lld:pubmed |
| pubmed-article:8189254 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8189254 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8189254 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8189254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8189254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8189254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8189254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8189254 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8189254 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8189254 | pubmed:issn | 0022-3042 | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:JacobsenPP | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:TreppendahlSS | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:ThomsenCC | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:SuzdakP DPD | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:JacksonH CHC | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:SheardownMM | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:KlitgaardHH | lld:pubmed |
| pubmed-article:8189254 | pubmed:author | pubmed-author:EskesenKK | lld:pubmed |
| pubmed-article:8189254 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8189254 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:8189254 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8189254 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8189254 | pubmed:pagination | 2492-5 | lld:pubmed |
| pubmed-article:8189254 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:meshHeading | pubmed-meshheading:8189254-... | lld:pubmed |
| pubmed-article:8189254 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8189254 | pubmed:articleTitle | (S)-4-carboxy-3-hydroxyphenylglycine, an antagonist of metabotropic glutamate receptor (mGluR) 1a and an agonist of mGluR2, protects against audiogenic seizures in DBA/2 mice. | lld:pubmed |
| pubmed-article:8189254 | pubmed:affiliation | Department of Receptor Neurochemistry, Novo Nordisk A/S, Måløv, Denmark. | lld:pubmed |
| pubmed-article:8189254 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:14816 | entrezgene:pubmed | pubmed-article:8189254 | lld:entrezgene |
| entrez-gene:108068 | entrezgene:pubmed | pubmed-article:8189254 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8189254 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8189254 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8189254 | lld:pubmed |
